Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

MabPlex Raises $71 Million for Biopharmaceutical CDMO Services

publication date: Jun 8, 2020

MabPlex International, a biologics CDMO located in Yantai, completed a $71 million Series B financing led by PE firms DT Capital Partners and Huajin Capital. Founded in 2013, MabPlex provides global CDMO services for biopharmaceuticals, including mAbs, recombinant proteins, ADCs and bispecifics. The company offers contract services that range from DNA to finished drug products. Its CHO cell line platform is designed to move candidates quickly through the development process. In early 2019, MabPlex closed a $59 million Series A financing from SDIC Venture Fund and Shenzhen Venture Capital, two state-owned investors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China